[
  {
    "ts": "2025-11-10T05:31:51+00:00",
    "headline": "5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call",
    "summary": "Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively as margin compression and operational investments weighed on sentiment. Management attributed top-line gains primarily to the ongoing expansion of its cystic fibrosis (CF) franchise and early strength from new launches in acute pain and genetic therapies. CEO Reshma Kewalramani pointed to “strong response from patients and physicians” for ALYFTREK and highlighted momentum w",
    "url": "https://finance.yahoo.com/news/5-insightful-analyst-questions-vertex-053151915.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "2737565d-a067-3e15-bca5-9177bbbfb44c",
      "content": {
        "id": "2737565d-a067-3e15-bca5-9177bbbfb44c",
        "contentType": "STORY",
        "title": "5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call",
        "description": "",
        "summary": "Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively as margin compression and operational investments weighed on sentiment. Management attributed top-line gains primarily to the ongoing expansion of its cystic fibrosis (CF) franchise and early strength from new launches in acute pain and genetic therapies. CEO Reshma Kewalramani pointed to “strong response from patients and physicians” for ALYFTREK and highlighted momentum w",
        "pubDate": "2025-11-10T05:31:51Z",
        "displayTime": "2025-11-10T05:31:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "VRTX Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l6Y31wu10RiElUns.3mORA--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Qe_uhCRKlCGgByoENi3GZg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/5-insightful-analyst-questions-vertex-053151915.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-insightful-analyst-questions-vertex-053151915.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]